1. DISEASE CHARACTERISTICS 1.1 Name of the disease (synonyms): Abetalipoproteinaemia (Bassen-Kornzweig syndrome).
OMIM# of the disease:
200100.
1.3 Name of the analysed genes or DNA/chromosome segments: MTTP.
OMIM# of the gene(s):
157147.
Mutational spectrum:
Over 30 variants in MTTP associated with abetaliopoproteinaemia have been described, mostly missense, nonsense and splicing variants located throughout the gene's 18 exons. [1] [2] [3] [4] [5] [6] The majority of variants associated with abetalipoproteinaemia are 'private' to specific families or ethnic communities.
Analytical methods:
DNA sequencing of genomic-exonic DNA with at least 20 bp of flanking intronic sequence. In patients where autosomal co-dominant inheritance cannot be excluded or MTTP variant(s) cannot be identified, the APOB gene should be screened as homozygous familial hypobetalipoproteinaemia can give a similar biochemical and clinical phenotype to abetalipoproteinaemia.
Analytical validation
Where a variant is identified using bi-directional DNA sequencing, the test is repeated from a fresh dilution of DNA for confirmation. When heterozygosity for two variants is found, testing of the patient's parents is recommended to confirm that the two variants are present in trans (ie, on opposite chromosomes).
1.8 Estimated frequency of the disease (Incidence at birth ('birth prevalence') or population prevalence):
Estimated at o1 in 1 000 000. 1 1.9 If applicable, prevalence in the ethnic group of investigated person: Not applicable.
Diagnostic setting:
Yes No
Comment: Use of genetic testing is essentially limited to confirmatory diagnosis in a subject suspected to be affected, rather than other applications such as predictive testing or prenatal diagnosis. 
TEST CHARACTERISTICS

2.6
Negative clinical predictive value (probability not to develop the disease if the test is negative) Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered. Index case in that family had been tested: 100%. Index case in that family had not been tested: Should the constellation of clinical findings be present in an index case, it is possible that they might have homozygous familial hypobetalipoproteinaemia, rather than abetalipoproteinaemia. Homozygous familial hypobetalipoproteinaemia patients receive similar treatment advice as abetalipoproteinaemia patients. Also, there are even rarer conditions called homozygous proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency and familial combined hypolipidaemia (due to homozygous variants in angiopoietin-like protein 3, ANGPTL3) that present with extremely low (but not absent) levels of apoB-containing lipoproteins, but no systemic manifestations. 4 In familial combined hypolipidaemia, high-density lipoprotein (HDL) cholesterol levels are also very low. To date, there are only a handful of families in the world reported with these latter two genetic conditions. 3.1.2 Describe the burden of alternative diagnostic methods to the patient Abetalipoproteinaemia is characterised by the absence of plasma apoBcontaining lipoproteins with marked hypocholesterolaemia, absence of LDL cholesterol and apoB, and low triglyceride concentrations. 1, 4, 5 In addition, increased serum aminotransferases due to hepatic steatosis, acanthocytosis and fat-soluble vitamin deficiency are found. Abetalipoproteinaemia cannot be distinguished from homozygous familial hypobetalipoproteinaemia clinically.
CLINICAL UTILITY
3.1.3
How is the cost effectiveness of alternative diagnostic methods to be judged? Not applicable.
Will disease management be influenced by the result of a genetic test?
No The impact of age at diagnosis, commencement of a low-fat diet and fat-soluble vitamin supplementation, and the findings from MTTP genomic sequencing in abetalipoproteinaemia are variable. Early treament with high-dose oral vitamin E and A can reduce the potential severity of neuropathy and retinopathy. 5, 10 A relative paucity of data makes it difficult to predict clinical outcomes based on MTTP genotype. The long-term outcome of hepatic steatosis in abtealipoproteinaemia is unknown but associations with hepatic steatohepatitis and cirrhosis have been reported. 11 
